Increase in blood SIRI levels elevates the risk of COPD: Study
A new study published in the International Journal of Chronic Obstructive Pulmonary Disease showed a non-linear association between the prevalence of chronic obstructive pulmonary disease (COPD) and serum inflammatory marker, systemic inflammation response index (SIRI) levels.
Airflow blockage and enduring respiratory symptoms are hallmarks of COPD, a complex lung ailment fueled by many pathogenic pathways. A forced expiratory volume in one second (FEV1) to forced vital capacity (FVC) ratio of less than 0.7, which represents the percentage of air forcibly expelled in one second as compared to the total volume exhaled following maximal inhalation, is the clinical diagnostic criteria for COPD.
Chronic inflammation can hasten the course of COPD. Based on the numbers of neutrophils, monocytes, and lymphocytes, the SIRI is a new and promising inflammatory biomarker. It provides a fresh viewpoint for assessing inflammatory reactions and acts as a gauge of the body's systemic inflammatory state. Thus, this study investigated any possible correlation between the prevalence of COPD and the levels of the serum inflammatory marker SIRI.
Data from the 2013–2018 National Health and Nutrition Examination Survey (NHANES) database were used in this cross-sectional investigation. After analysis, 10,273 participants were split into two groups: those with COPD (n = 595) and those without (n = 9678). Between cohorts, a comparative examination of clinical and demographic traits was conducted.
The SIRI was computed using the lymphocyte, neutrophil, and monocyte numbers. The link between SIRI and COPD was evaluated using weighted logistic regression models, and any non-linear associations were examined using restricted cubic spline (RCS) curves. Subgroup and interaction studies were also carried out.
There were 10,273 individuals participating in the research; 595 of them had a COPD diagnosis, and 9678 did not.
SIRI and COPD showed a significant positive correlation in the fully adjusted logistic regression model (OR = 1.96, 95% CI = 1.34–2.87).
A non-linear association between SIRI and COPD was found by analyzing the RCS curve (P < 0.05).
The robustness of the findings was further validated by subgroup and interaction analysis.
Overall, elevated blood SIRI levels were shown to be substantially linked to an increased risk of COPD in this cross-sectional investigation based on the NHANES database. This suggests that SIRI might be a new inflammatory measure that can be used to predict the onset of COPD.
Reference:
Chen, Y., Pei, Y., Mo, W., & Wang, H. (2025). The relationship between serum inflammatory markers and chronic obstructive pulmonary disease in middle-aged and older adults in the United States: A cross-sectional study based on NHANES 2013–2018. International Journal of Chronic Obstructive Pulmonary Disease, 20, 2837–2846. https://doi.org/10.2147/copd.s534504
